bluebird bio (BLUE) : The short interest in bluebird bio (BLUE) has increased from 8,332,881 to 8,518,630 from Jul 29, 2016, to August 15, 2016, indicating that the traders are bearish on the stock. On an average, 917,815 shares are traded daily in the stock and only 9 days are left for the shorts to cover. The short open interest is 23.5% of the total shares in the hands of the public. The shorts in the stock have gone up by 185,749 shares, which is an increase of 2.2% over the previous reading. The short interest information was released on Wednesday Aug 24th after the market close.
bluebird bio (NASDAQ:BLUE): The stock opened at $54.79 on Wednesday but the bulls could not build on the opening and the stock topped out at $57.00 for the day. The stock traded down to $49.95 during the day, due to lack of any buying support eventually closed down at $50.26 with a loss of -8.47% for the day. The stock had closed at $54.91 on the previous day. The total traded volume was 1,673,940 shares.
In a related news, The officer (Principal Accounting Officer), of Bluebird Bio, Inc., Sullivan Eric had unloaded 416 shares at $59 per share in a transaction on August 3, 2016. The total value of transaction was $24,544. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Companys products include Lenti-D, LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy), the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States, Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.